Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
An allergy is the immune system’s reaction to an unidentified substance that’s not usually harmful to your body. These substances are known as allergens. They contain, pollens, certain foods and dust mites. Mites are primitive creatures that have no eyes and not respiratory systems. These mites can be seen through microscopes only. Furthermore, Life cycle of dust mites consists of several stages from egg to adult. Dust mites thrive in temperatures of 68-77° F and relative humidity levels from 70-80%. According to the report, household dust is the mixture of several materials. Moreover, Dust may contain tiny particles of insect parts, plant and food, feathers from birds. In addition, it could also hold dander from pet dogs or cats. Dust also has waste products of several microscopic mites. The waste products of dust mites cause allergic reaction in sensitive individuals. Medications used for house dust mite energy: Antihistamines and decongestants are the most common allergy medications. These medications help in reducing sneezing, itching, stuffy nose and runny nose. Several other medications work by preventing of the chemicals causing allergic reactions. Also, corticosteroid sprays are very effective in curing inflammation in your nose. Allergy shots work progressively by augmenting person’s tolerance to allergy triggers. On the basis of geography, The U.S is considered to be the most dominating region for house dust mite allergy. Asthma and energy foundation of America stated that, around 20 million people in America are suffering from house dust mite allergy. In addition, house dust mite allergy is prevalent worldwide. Approximately more than 20% of the European populations are skin-prick test positive for house dust mites. House dust mite actually impact the way people can function at work and at home. Management: Dusting and vacuuming the house on a regular basis won’t be sufficient to eliminate waste and dust mites. In addition, more than 95% of the mites may reside after vacuuming as they live inside toys, upholstered furniture, stuffed animals and pillows.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 House Dust Mite Allergy Overview 6 Therapeutics Development 7 Pipeline Products for House Dust Mite Allergy - Overview 7 Pipeline Products for House Dust Mite Allergy - Comparative Analysis 8 House Dust Mite Allergy - Therapeutics under Development by Companies 9 House Dust Mite Allergy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 House Dust Mite Allergy - Products under Development by Companies 13 House Dust Mite Allergy - Companies Involved in Therapeutics Development 14 ALK-Abello A/S 14 Anergis SA 15 Biomay AG 16 Circassia Pharmaceuticals plc 17 DBV Technologies S.A. 18 HAL Allergy BV 19 Stallergenes S.A. 20 House Dust Mite Allergy - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 AllerDM - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 allergenic pollen extract of timothy - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 BM-35 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 House Dust Mite-SPIRE - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 MK-8237 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PL-103 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 S-524101 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Viaskin House Dust Mite - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 House Dust Mite Allergy - Recent Pipeline Updates 39 House Dust Mite Allergy - Dormant Projects 43 House Dust Mite Allergy - Discontinued Products 44 House Dust Mite Allergy - Product Development Milestones 45 Featured News & Press Releases 45 Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet 45 Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet 45 Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development 46 Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet 47 Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction 48 Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 49 Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment 50 Jun 19, 2013: ALK-Abello's New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy 51 Nov 14, 2012: DBV Technologies Launches Third Viaskin Program For Treatment Of House Dust Mites Allergy In Young Children 51 Oct 10, 2012: Merck Plans To Initiate Phase III Clinical Trial With HDM AIT In North America 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables Number of Products under Development for House Dust Mite Allergy, H1 2015 7 Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H1 2015 14 House Dust Mite Allergy - Pipeline by Anergis SA, H1 2015 15 House Dust Mite Allergy - Pipeline by Biomay AG, H1 2015 16 House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015 17 House Dust Mite Allergy - Pipeline by DBV Technologies S.A., H1 2015 18 House Dust Mite Allergy - Pipeline by HAL Allergy BV, H1 2015 19 House Dust Mite Allergy - Pipeline by Stallergenes S.A., H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 26 House Dust Mite Allergy Therapeutics - Recent Pipeline Updates, H1 2015 39 House Dust Mite Allergy - Dormant Projects, H1 2015 43 House Dust Mite Allergy - Discontinued Products, H1 2015 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
